Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery
Based on technology from SkylineDx, the test aims to aid treatment decisions for patients with the deadliest form of skin cancer
Patients classified as low-risk by MelaNodal Predict are shown to have survival rate of over 90 percent
MelaNodal Predict is a lab-developed test validated by
This insight may help providers identify patients that could, with less risk, avoid a potentially unnecessary, expensive and invasive surgery called a sentinel lymph node biopsy (SLNB). If the algorithm classifies a patient as low risk, they may be able to choose to forgo the procedure. More than 8 in 10 patients who have an SLNB are negative for nodal metastasis, based on post-surgical analysis.2
"Melanoma test services are an important component of our broad portfolio of advanced oncology tests," said
By reducing SLNB interventions, providers who utilize the test may be able to more effectively use healthcare resources and manage patient risk. It is estimated that patients who receive an SLNB have a greater than 10% risk of surgery-related complications including bleeding, infection and limb swelling.3 The test also provides insights on a patient's long-term outcome, as patients with a low-risk result have reported better survival rates. All studies of the algorithm utilized have reported minimal follow up after five years,4 and recent data from 6 US institutions shows that patients the algorithm classified as low risk have a survival rate of more than 90 percent.5
"This relationship between Quest and SkylineDx is a testament to the transformative impact that innovative collaborations can have in healthcare. SkylineDx's expertise in molecular diagnostics, coupled with
This collaboration aims to combine SkylineDx's innovative technology with Quest's expertise and national scale in
About SkylineDx
SkylineDx is a biotechnology company focused on research and development of molecular diagnostics in oncology and inflammatory diseases. SkylineDx uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, assisting healthcare professionals in accurately determining the type or status of disease or predicting a patient's response to treatment. Based on test results, healthcare professionals can tailor the treatment approach to the individual patient. SkylineDx is headquartered in
About
1 Melanoma Skin Cancer Statistics |
2
3 Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, Gabram SG, Lucci A, Cox CE, Hunt KK, Herndon JE 2nd, Giuliano AE. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006 Apr;13(4):491-500. doi: 10.1245/ASO.2006.05.013. Epub 2006
4 Amaral T, Sinnberg T, Chatziioannou E, et al. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP). Eur J Cancer. 2023;182:155-162. doi:10.1016/j.ejca.2022.12.021
5 Multicenter US Study Reveals CP-GEP's Profound Impact on Stratifying Melanoma Patients for Long-Term Survival - SkylineDx
View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-debuts-melanodal-predict-test-personalizing-melanoma-risk-prediction-to-help-patients-forgo-invasive-surgery-302060012.html
SOURCE